Novartis (NOVN) Q3 2024 earnings summary

Executive summary

• Achieved strong operational performance in Q3 2024, with net sales up 10% to $12.8 billion and core operating income up 20% year-over-year in constant currencies, driven by key brands and innovation milestones.

• Raised full-year 2024 guidance for both top and bottom line for the third time, reflecting sustained business momentum and pipeline progress.

• Completed transformation into a pure-play innovative medicines business following the Sandoz spin-off in October 2023.

• Key product launches and regulatory milestones included Kisqali's FDA approval in early breast cancer, Fabhalta's accelerated approval in IgA nephropathy, and Pluvicto's PSMA4 filing acceptance.

• Free cash flow reached $6.0 billion in Q3 (+18%), with robust pipeline activity and major acquisitions reshaping the business.

Financial highlights

• Q3 net sales: $12.8 billion (+10% cc); core operating income: $5.1 billion (+20% cc); core margin: 40.1% (+340 bps); core EPS: $2.06 (+20% cc); free cash flow: $6.0 billion (+18%).

• Nine months net sales: $37.2 billion (+11% cc); core operating income: $14.6 billion (+20% cc); free cash flow: $12.6 billion (+15%).

• Q3 operating income: $3.6 billion (+123% cc); net income: $3.2 billion (+121% cc); EPS: $1.58 (+127% cc).

• Net debt as of September 30, 2024: $16.3 billion, up from $10.2 billion at year-end 2023.

Outlook and guidance

• Full-year 2024 net sales expected to grow low double-digit (previously high single to low double-digit); core operating income expected to grow high teens (previously mid to high teens).

• Assumes no US generic entries for Tasigna, Promacta, or Entresto in 2024; generics expected mid-2025 for modeling.

• Core tax rate expected around 16.2% for the full year.

• Midterm guidance reaffirmed: 5%+ sales CAGR (2023–2028) and 40%+ core operating margin by 2027.